After today's market close, the San Diego-based biopharmaceutical company posted a net loss of 13 cents per share. The loss was in line with analysts' expectations.
Revenue for the period was $7.75 million, missing Wall Street's projections of $8.26 million.
"Arena took a number of important steps in 2015, including initiating two Phase 2 clinical trials, partnering two of our programs, filing a new drug application and reducing our internal expenses," Interim CEO Harry F. Hixson said in a statement.
"We entered 2016 focused on advancing our internal and partnered clinical-stage compounds that we believe will highlight the intrinsic value of our pipeline and the strength of our R&D capabilities," he added.
Separately, TheStreet Ratings Team has a "Sell" rating with a score of D- on the stock.
This is driven by a number of negative factors, which should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks covered.
The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
You can view the full analysis from the report here: ARNA